文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症患者万古霉素给药方案优化的研究

[Study on the optimization of administration regimen of vancomycin in critical patients].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论重症患者同等日剂量下增加万古霉素给药频次可升高谷浓度、降低峰浓度并减小血药浓度波动,但不影响AUC0-24h/MIC达标率。

该回顾性研究纳入上海交通大学医学院附属瑞金医院ICU 2011年1月至2018年12月接受万古霉素治疗并记录稳态谷浓度(Cmin)的患者285例、共529条Cmin记录,按给药间隔分为q12h组(375条)、q8h组(121条)、q6h组(33条)。用JPKD Ver 3.1统一日剂量后,q12h组、q8h组、q6h组Cmin(10-20 mg/L)达标率分别为35.7%、43.8%、60.6%,仅q12h组与q6h组比较有统计学意义(P<0.01)。q6h组和q8h组Cmin高于q12h组、峰浓度(Cmax)低于q12h组,但三组PD靶标(AUC0-24h/MIC≥400)达标率无显著差异。作者认为重症患者万古霉素给药方案应根据肌酐清除率、万古霉素清除率和年龄优化。

要点

  • 统一日剂量后,q12h组、q8h组、q6h组Cmin(10-20 mg/L)达标率分别为35.7%、43.8%、60.6%,仅q12h组与q6h组比较有统计学意义(P<0.01)。
  • q6h组和q8h组Cmin高于q12h组(mg/L:13.8±5.2、13.5±7.3 vs. 11.4±7.9,均P<0.05),Cmax低于q12h组(mg/L:19.4±5.3、21.5±7.3 vs. 23.9±8.1,均P<0.05)。
  • 三组PD靶标(AUC0-24h/MIC≥400)达标率分别为38.1%、41.3%、45.5%,无显著差异(P>0.05)。
  • 肌酐清除率和万古霉素清除率是Cmin和AUC0-24h/MIC的主要影响因素(r值分别为-0.391、-0.424和-0.673、-0.663,均P<0.01),且与年龄呈负相关(r值分别为-0.432和-0.488,均P<0.01)。
  • 作者认为重症患者万古霉素给药方案应根据肌酐清除率、万古霉素清除率和年龄优化。

适用人群与场景

  • 上海交通大学医学院附属瑞金医院ICU 2011年1月至2018年12月接受万古霉素治疗并记录稳态谷浓度(Cmin)的重症患者285例,共529条Cmin记录。

诊断标准与关键阈值

  • Cmin目标范围10-20 mg/L。
  • PD靶标为AUC0-24h/MIC≥400。

处置流程与药物剂量

  • 按给药间隔分为q12h组(375条数据)、q8h组(121条数据)、q6h组(33条数据)。
  • 用JPKD Ver 3.1统一日剂量后评估Cmin达标率。
  • 用JPKD Ver 3.1估算给药前(0小时)及给药后1、2、4、6、8、12、24小时的血药浓度,用梯形面积法估算AUC0-24h,检索同期病原微生物最低抑菌浓度(MIC)计算AUC0-24h/MIC。

研究设计与关键结果

  • 回顾性研究纳入285例患者529条Cmin记录,q12h组375条、q8h组121条、q6h组33条。
  • 统一日剂量后Cmin(10-20 mg/L)达标率:q12h组35.7%、q8h组43.8%、q6h组60.6%,仅q12h组与q6h组比较有统计学意义(P<0.01)。
  • q6h组和q8h组Cmin高于q12h组(mg/L:13.8±5.2、13.5±7.3 vs. 11.4±7.9,均P<0.05),Cmax低于q12h组(mg/L:19.4±5.3、21.5±7.3 vs. 23.9±8.1,均P<0.05)。
  • 三组PD靶标(AUC0-24h/MIC≥400)达标率分别为38.1%、41.3%、45.5%,无显著差异(P>0.05)。
  • 多因素线性回归显示肌酐清除率和万古霉素清除率是Cmin和AUC0-24h/MIC的主要影响因素(r值分别为-0.391、-0.424和-0.673、-0.663,均P<0.01),且与年龄呈负相关(r值分别为-0.432和-0.488,均P<0.01)。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为同等日剂量下增加万古霉素给药频次可升高Cmin、降低Cmax,从而减小血药浓度波动,但不影响AUC0-24h/MIC。
  • 作者认为重症患者万古霉素给药方案应根据肌酐清除率、万古霉素清除率和年龄优化。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the changing characteristics of pharmacokinetic and pharmacodynamic (PK-PD) parameters of vancomycin in critical patients under different drug regimens and to further explore the influencing factors.

METHODS: The clinical data of patients who treated with vancomycin and recorded by steady-state through concentration (Cmin) admitted to intensive care unit (ICU) of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2011 to December 2018 were analyzed retrospectively. The patients were divided into three groups according to the dosing interval (groups of q12 h, q8 h and q6 h respectively) and Cmin was collected. The serum concentration of vancomycin before (0 hour) and 1, 2, 4, 6, 8, 12 and 24 hours after administration were estimated by JPKD Ver 3.1. Area under the curve (AUC0-24 h) was estimated by trapezoidal area method. Minimum inhibitory concentration (MIC) of pathogenic microorganisms in the same period was retrieved, thus AUC0-24 h/MIC was calculated.

RESULTS: 285 patients with 529 records of Cmin were enrolled in the study, including 375 data in q12 h group, 121 data in q8 h group and 33 data in q6 h group. After unifying daily dose by JPKD Ver 3.1, the Cmin (10-20 mg/L) reaching rate of q12 h group, q8 h group, q6 h group were 35.7%, 43.8% and 60.6%, respectively, while only q12 h group was statistically significant compared with q6 h group (P < 0.01). q6 h group and q8 h group showed higher Cmin than q12 h group (mg/L: 13.8±5.2, 13.5±7.3 vs. 11.4±7.9, both P < 0.05) and lower peak concentration (Cmax) than q12 h group (mg/L: 19.4±5.3, 21.5±7.3 vs. 23.9±8.1, both P < 0.05). However, there was no significant difference in terms of percentage of PD target (AUC0-24 h/MIC ≥ 400) among the three groups (q12 h group, q8 h group, q6 h group were 38.1%, 41.3%, 45.5%, P > 0.05). Multiple linear regression analysis showed that creatinine clearance (CCr) and vancomycin clearance (CLvancomycin) were the main influencing factors of vancomycin PD parameters such as Cmin and AUC0-24 h/MIC (r values of CCr were -0.391, -0.424, and rvalues of CLvancomycin were -0.673, -0.663, all P < 0.01), and were negatively correlated with age (r values were -0.432 and -0.488, respectively, both P < 0.01).

CONCLUSIONS: At the same daily dose, Cmin can be increased and Cmax can be decreased by increasing the frequency of vancomycin administration, thus minimize the fluctuation of vancomycin serum concentration, but AUC0-24 h/MIC is not affected. Vancomycin administration regimen in severe patients should be optimized according to CCr, CLvancomycin and age.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Shi Y, He J, Mao E, et al. [Study on the optimization of administration regimen of vancomycin in critical patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32274995. doi:10.3760/cma.j.cn121430-20190905-00026

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。